ascites

Summary

Summary: Accumulation or retention of free fluid within the peritoneal cavity.

Top Publications

  1. doi Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?
    Sebastian Kobold
    Department of Oncology Hematology Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Oncologist 14:1242-51. 2009
  2. ncbi Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
    Diane Seimetz
    Fresenius Biotech GmbH, Frankfurter Ring 193a, D 80807 München, Munich, Germany
    Cancer Treat Rev 36:458-67. 2010
  3. ncbi Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death
    Douglas M Heuman
    Department of Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA
    Hepatology 40:802-10. 2004
  4. ncbi Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites
    Thomas Sersté
    Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de recherche Biomedicale Bichat Beaujon, Paris, France
    Hepatology 52:1017-22. 2010
  5. doi Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity
    Peng Peng
    Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing 100730, PR China
    Oncol Rep 25:749-62. 2011
  6. doi Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model
    Yi Yu Lin
    Biomedical Imaging and Radiological Sciences, National Yang Ming University, Taipei, Taiwan, Republic of China
    Cancer Biother Radiopharm 24:453-60. 2009
  7. ncbi Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
    Walter H Gotlieb
    McGill University, Jewish General Hospital, Montreal, QC, Canada
    Lancet Oncol 13:154-62. 2012
  8. pmc Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites
    R Frances
    Department of Immunology, Hospital General Universitario, Pintor Baeza s n, Alicante, Spain
    Gut 53:860-4. 2004
  9. ncbi Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model
    Annette T Byrne
    Center for Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143, USA
    Clin Cancer Res 9:5721-8. 2003
  10. ncbi Proinvasive properties of ovarian cancer ascites-derived membrane vesicles
    Laura E Graves
    Department of Cellular and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Cancer Res 64:7045-9. 2004

Detail Information

Publications312 found, 100 shown here

  1. doi Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?
    Sebastian Kobold
    Department of Oncology Hematology Bone Marrow Transplantation with the Section Pneumology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Oncologist 14:1242-51. 2009
    Despite overall improvements in oncological care in the palliative setting, symptomatic malignant ascites remains a severe clinical problem. This form of effusion is known to be widely resistant to established modes of systemic therapy...
  2. ncbi Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
    Diane Seimetz
    Fresenius Biotech GmbH, Frankfurter Ring 193a, D 80807 München, Munich, Germany
    Cancer Treat Rev 36:458-67. 2010
    ..Catumaxomab has been approved in the European Union since April 2009 for the i.p. treatment of malignant ascites (MA) in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible...
  3. ncbi Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death
    Douglas M Heuman
    Department of Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA
    Hepatology 40:802-10. 2004
    ..MELD score, persistent ascites, and low serum sodium (<135 meq/L) were independent predictors of early mortality...
  4. ncbi Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites
    Thomas Sersté
    Institut National de la Santé et de la Recherche Médicale Unité 773, Centre de recherche Biomedicale Bichat Beaujon, Paris, France
    Hepatology 52:1017-22. 2010
    Beta-blockers may have a negative impact on survival in patients with cirrhosis and refractory ascites. The aim of this study was to evaluate the effect of the administration of beta-blockers on long-term survival in patients with ..
  5. doi Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity
    Peng Peng
    Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing 100730, PR China
    Oncol Rep 25:749-62. 2011
    This study was performed to identify the origin of the ascites-derived exosomes from patients with ovarian cancer and to observe the effect of exosomes on anti-tumor immunity...
  6. doi Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model
    Yi Yu Lin
    Biomedical Imaging and Radiological Sciences, National Yang Ming University, Taipei, Taiwan, Republic of China
    Cancer Biother Radiopharm 24:453-60. 2009
    ..p.) and intravenous (i.v.) administration in a C26/tk-luc colon carcinoma ascites mouse model. IVNBPL was prepared by labeling VNB-encapsulated PEGylated liposomes with 111In-oxine...
  7. ncbi Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
    Walter H Gotlieb
    McGill University, Jewish General Hospital, Montreal, QC, Canada
    Lancet Oncol 13:154-62. 2012
    Targeting of VEGF is a potential therapeutic option in patients with malignant ovarian ascites. We present the final results of a multicentre study of the efficacy and safety of aflibercept, a potent inhibitor of both VEGF and placental ..
  8. pmc Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites
    R Frances
    Department of Immunology, Hospital General Universitario, Pintor Baeza s n, Alicante, Spain
    Gut 53:860-4. 2004
    ....
  9. ncbi Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model
    Annette T Byrne
    Center for Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143, USA
    Clin Cancer Res 9:5721-8. 2003
    ..It is characterized by diffuse peritoneal carcinomatosis and often by large volumes of i.p. ascites. Because vascular endothelial growth factor (VEGF), also known as vascular permeability factor, increases ..
  10. ncbi Proinvasive properties of ovarian cancer ascites-derived membrane vesicles
    Laura E Graves
    Department of Cellular and Molecular Biology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Cancer Res 64:7045-9. 2004
    Malignant ovarian ascites are rich in cellular components, membrane-bound vesicles, and soluble proteins...
  11. ncbi Ovarian cancer metastasis: integrating insights from disparate model organisms
    Honami Naora
    Department of Molecular Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Nat Rev Cancer 5:355-66. 2005
    ..Genetic analysis of border-cell migration in the Drosophila melanogaster ovary provides clues that will improve our understanding of ovarian cancer metastasis at the molecular level, and also might lead to potential therapeutic targets...
  12. ncbi Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers
    Kathryn M Burleson
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
    Gynecol Oncol 93:170-81. 2004
    ..The current paradigm that ascites spheroids are non-adhesive leaves their contribution to ovarian carcinoma dissemination undefined...
  13. ncbi Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors
    Marek Nowak
    Department of Gynecologic Surgery, Polish Mother s Memorial Hospital Research Institute, Poland
    Neuro Endocrinol Lett 31:375-83. 2010
    ..factor-beta1 (TGF-beta1) and interferon-gamma (IFN-gamma) in serum and the tumor microenvironment (cyst fluid, ascites) in women with ovarian cancer or benign ovarian tumors to find the differences in their immunological status...
  14. pmc Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers
    Cynthia Kuk
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario M5G 1L5, Canada
    Mol Cell Proteomics 8:661-9. 2009
    ..We performed an in-depth proteomics analysis of ovarian cancer ascites fluid...
  15. ncbi Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation
    Dorina Belotti
    Laboratory of Biology, Department of Oncology, Mario Negri Institute for Pharmacological Research, 24125 Bergamo, Italy
    Cancer Res 63:5224-9. 2003
    ..Levels of MMP9 (pro and activated form) and proMMP2 in ascites correlated with VEGF and with the ascitic volume in nude mice bearing human ovarian carcinoma xenografts (HOC22 ..
  16. ncbi A bivariate mixture model analysis of body weight and ascites traits in broilers
    S Zerehdaran
    Animal Breeding and Genetics Group, Wageningen Institute of Animal Science, The Netherlands
    Poult Sci 85:32-8. 2006
    ..of the present study was to use bivariate mixture models to study the relationships between body weight (BW) and ascites indicator traits...
  17. ncbi Disease-induced variability of genetic correlations: ascites in broilers as a case study
    K H de Greef
    Institute for Animal Science and Health, Lelystad, The Netherlands
    J Anim Sci 79:1723-33. 2001
    ..b>Ascites in broilers is such a disease...
  18. pmc Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer
    Limin Hu
    Center for Reproductive Sciences, University of California at San Francisco 94143, USA
    Am J Pathol 161:1917-24. 2002
    Ovarian cancer is characterized by rapid growth of solid intraperitoneal tumors and production of large volumes of ascites. Our previous studies of intraperitoneal ovarian carcinoma in an athymic mouse model demonstrated that a ..
  19. doi Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis
    Marlene Pasquet
    EA3035, Institut Claudius Regaud, University Toulouse III, Faculte des sciences pharmaceutiques, Toulouse, F 31062, France
    Int J Cancer 126:2090-101. 2010
    ..Cells closely associated with tumoral cells, named hospicells, have been recently isolated from the ascites of ovarian cancer patients...
  20. ncbi Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child's status
    M Wadhawan
    Department of Gastroenterology, G B Pant Hospital, New Delhi, 110002, India
    Dig Dis Sci 51:2264-9. 2006
    ..The HVPG was comparable between hepatitis B- and hepatitis C virus-related cirrhotics (P = 0.8). Cirrhotics with ascites had a higher HVPG than those without ascites (18.5 +/- 5.6 vs 16.6 +/- 7.6 mm Hg; P = 0.02)...
  21. doi Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients
    Zheng Zhang
    Research Center for Biological Therapy, The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China
    J Gastroenterol Hepatol 27:112-20. 2012
    ..There was a significant reduction in the volume of ascites in patients treated with UC-MSC transfusion compared with controls (P < 0.05)...
  22. pmc Antitumor activity of silver nanoparticles in Dalton's lymphoma ascites tumor model
    Muthu Irulappan Sriram
    Department of Biotechnology, Division of Molecular and Cellular Biology, Kalasalingam University, Tamilnadu, India
    Int J Nanomedicine 5:753-62. 2010
    ..efficacy of biologically synthesized silver nanoparticles (AgNPs) as an antitumor agent using Dalton's lymphoma ascites (DLA) cell lines in vitro and in vivo...
  23. doi A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites
    Nicoletta Colombo
    Istituto Europeo di Oncologia, Divisione di Ginecologia, Via Ripamonti, Milano, Italy
    Gynecol Oncol 125:42-7. 2012
    ..Aflibercept inhibits ascites formation and reduces tumor burden in an ovarian cancer model...
  24. ncbi Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer
    Yoko Hasumi
    Division of Genetic Therapeutics, Jichi Medical School, Tochigi 329 0498, Japan
    Cancer Res 62:2019-23. 2002
    ..and stimulating endothelial growth, is thought to be responsible for fluid accumulation and angiogenesis in ascites tumors...
  25. pmc Guidelines on the management of ascites in cirrhosis
    K P Moore
    The UCL Institute of Hepatology, Royal Free and University College Medical School, UCL, Rowland Hill St, London NW3 2PF, UK
    Gut 55:vi1-12. 2006
  26. ncbi CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers
    Ilona Kryczek
    Tulane University Health Science Center, New Orleans, LA 70112, USA
    Cancer Res 65:465-72. 2005
    ..To examine tumor angiogenesis in the tumor microenvironment, we studied malignant ascites and tumors of patients with untreated ovarian carcinoma...
  27. pmc Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer
    G Scambia
    Department of Gynecology and Obstetrics, Catholic University, Rome, Italy
    Br J Cancer 71:354-6. 1995
    ..0009). Multivariate analysis revealed that IL-6 positivity has an independent value...
  28. doi Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review
    Filippo Bellati
    Institute of Gynecology and Obstetrics, Sapienza University, Rome, Italy
    Invest New Drugs 28:887-94. 2010
    Malignant ascites resistant to conventional drugs frequently affects ovarian cancer patients at the end of life...
  29. doi Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer
    Shengming Dai
    Department of Oncology, Institute of Clinical Medicine, The Fourth Hospital Affiliated to Guangxi Medical University, Liuzhou, People s Republic of China
    Mol Ther 16:782-90. 2008
    ..In this study we report the phase I clinical trial of the ascites-derived exosomes (Aex) in combination with the granulocyte-macrophage colony-stimulating factor (GM-CSF) in the ..
  30. ncbi Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation
    D Lane
    Departement De Microbiologie et Infectiologie, Faculte de Medecine, Universite de Sherbrooke, Sherbrooke, Canada
    Oncogene 29:3519-31. 2010
    ..We have earlier shown that ovarian cancer ascites induces Akt activation and protect tumor cells from TRAIL-induced apoptosis...
  31. ncbi Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model
    Limin Hu
    Center for Reproductive Sciences, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143 0556, USA
    Clin Cancer Res 11:6966-71. 2005
    Ovarian cancer is characterized by i.p. carcinomatosis and massive ascites. Vascular endothelial growth factor (VEGF) plays a pivotal role in tumor angiogenesis and vascular leakage leading to ascites...
  32. doi Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice model
    Liang Cheng Chen
    Institute of Nuclear Energy Research, Taoyuan, Taiwan
    Nucl Med Biol 35:883-93. 2008
    ..pegylated liposomal doxorubicin ((188)Re-DXR-liposome) were investigated in the C26 murine colon carcinoma ascites mouse model...
  33. doi IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer
    Chi Wen Lo
    Department of Oncology, National Taiwan University Hospital, Institute of Toxicology, National Taiwan University College of Medicine, Nankang, Taiwan
    Cancer Res 71:424-34. 2011
    ..Here we report that sIL-6Rα is elevated in malignant ascites from ovarian cancer patients, where it is associated with poor prognosis...
  34. ncbi Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM
    Steffen Runz
    Tumor Immunology Programme D010, German Cancer Research Center, Im Neuenheimer Feld 580, D 69120 Heidelberg, Germany
    Gynecol Oncol 107:563-71. 2007
    ..Given the emerging role of exosomes in tumor progression, we investigated whether cytoplasmic CD24 expression is correlated with the secretion of CD24 in exosomes...
  35. pmc The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
    Markus M Heiss
    Department of Surgery, Cologne Merheim Medical Center, University of Witten Herdecke, Cologne, Germany
    Int J Cancer 127:2209-21. 2010
    Malignant ascites is a common manifestation of advanced cancers, and treatment options are limited...
  36. doi Ascitic fluid infection in patients with hepatitis B virus-related liver cirrhosis: culture-negative neutrocytic ascites versus spontaneous bacterial peritonitis
    Seung Up Kim
    Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
    J Gastroenterol Hepatol 25:122-8. 2010
    Ascitic fluid infection (AFI) consists of culture-negative neutrocytic ascites (CNNA) and spontaneous bacterial peritonitis (SBP)...
  37. doi Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites
    Seung Up Kim
    Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, South Korea
    J Gastroenterol Hepatol 23:1722-7. 2008
    Few studies have assessed the natural history of hepatitis B virus (HBV)-related cirrhotic ascites. We investigated the natural history of patients with HBV-related cirrhotic ascites hospitalized to control ascites and determined their ..
  38. ncbi Clinical characteristics and outcome of patients with cirrhosis and refractory ascites
    Richard Moreau
    Service d Hépatologie and INSERM U 481, 92118 Clichy, France
    Liver Int 24:457-64. 2004
    In patients with cirrhosis, refractory ascites is associated with a poor prognosis and is an indication for liver transplantation. However, factors that determine prognosis remain unclear.
  39. doi Niche-dependent tumorigenic capacity of malignant ovarian ascites-derived cancer cell subpopulations
    Ehood Katz
    Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology, Haifa, Israel
    Clin Cancer Res 15:70-80. 2009
    ..cellular microenvironment in supporting the growth of human cancer cells freshly harvested from malignant ovarian ascites and to determine whether there are differences among subsets of ascites-derived cancer cells in terms of ..
  40. ncbi The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation
    Carlos Guarner
    Liver Section, Escuela de Patologia Digestiva, Hospital de la Sta Creu i St Pau, Barcelona, and Liver Unit, Hospital General Universitario, Alicante, Spain
    Hepatology 44:633-9. 2006
    Bacterial DNA (bactDNA) is present in blood and ascitic fluid (AF) in a third of patients with cirrhosis and ascites, but whether this phenomenon represents episodes of bacterial translocation (BT), strictly considered when culture of ..
  41. ncbi Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response
    Martina Crysandt
    Medizinische Klinik IV, Universitaetsklinikum Aachen, RWTH Aachen, Aachen, Germany
    Eur J Haematol 79:546-9. 2007
    ..The patient's general status declined and she developed massive ascites as the dominant clinical problem...
  42. doi Malignant ascites symptom cluster in patients referred for paracentesis
    Amna Husain
    Temmy Latner Centre for Palliative Care, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
    Ann Surg Oncol 17:461-9. 2010
    Malignant ascites (MA) is a distressing problem usually managed by repeated paracenteses. Paracentesis represents a meaningful time point in identifying patients with a specific presentation.
  43. pmc Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors
    Ardian Latifi
    Women s Cancer Research Centre, Royal Women s Hospital, Victoria, Australia
    PLoS ONE 7:e46858. 2012
    Tumor cells in ascites are a major source of disease recurrence in ovarian cancer patients...
  44. doi Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration
    Monica Guevara
    Liver Unit Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
    Liver Int 30:1137-42. 2010
    ..intrahepatic portosystemic shunts (TIPS) vs large-volume paracentesis in the management of refractory of ascites. Variables used in the analysis included age, sex, previous history of HE, treatment assignment (TIPS vs large ..
  45. doi Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study
    Peter Jepsen
    Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
    Hepatology 51:1675-82. 2010
    ..We examined prevalence, risk, chronology, and mortality associated with three complications of cirrhosis: ascites, variceal bleeding, and hepatic encephalopathy...
  46. ncbi Genetic parameters of ascites-related traits in broilers: effect of cold and normal temperature conditions
    A Pakdel
    Animal Breeding and Genetics Group, Wageningen Institute of Animal Sciences, Wageningen, The Netherlands
    Br Poult Sci 46:35-42. 2005
    1) Ascites syndrome is a growth-related disorder of broilers that occurs more often in fast-growing birds and at low temperatures...
  47. pmc Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
    Denis Lane
    Departement De Microbiologie et Infectiologie, Faculte de Medecine, Universite de Sherbrooke, 3001, 12ième Avenue Nord, Sherbrooke, J1H 5N4, Canada
    BMC Cancer 11:210. 2011
    The acellular fraction of epithelial ovarian cancer (EOC) ascites promotes de novo resistance of tumor cells and thus supports the idea that tumor cells may survive in the surrounding protective microenvironment contributing to disease ..
  48. ncbi LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites
    Mayumi Komachi
    Laboratory of Signal Transduction, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan
    Carcinogenesis 30:457-65. 2009
    Malignant ascites from pancreatic cancer patients has been reported to stimulate migration of pancreatic cancer cells through lysophosphatidic acid (LPA) and LPA(1) receptors...
  49. ncbi The use of albumin in all patients with decompensated cirrhosis is not justified
    Benjamin Avidan
    Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel
    Isr Med Assoc J 7:118-20. 2005
  50. ncbi Renal replacement therapy in end-stage renal disease patients with chronic liver disease and ascites: role of peritoneal dialysis
    Kunal Chaudhary
    Division of Nephrology, University of Missouri Health Center, Columbia, MO 65203, USA
    Perit Dial Int 28:113-7. 2008
    ..ESRD patients with chronic liver disease and ascites are more difficult to manage on hemodialysis (HD) due to their hemodynamic status and risk of bleeding...
  51. doi A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites
    S Barni
    Division of Medical Oncology, Azienda Ospedaliera Treviglio Caravaggio, Treviglio Caravaggio Hospital, Treviglio BG, Italy
    Crit Rev Oncol Hematol 79:144-53. 2011
    Malignant ascites is defined as a condition in which fluid containing cancer cells accumulates in the abdomen...
  52. doi Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity
    Florence Wong
    Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
    Gut 61:108-16. 2012
    Satavaptan, a vasopressin V2 receptor antagonist, has been shown to improve the control of ascites in cirrhosis in short-term phase II studies...
  53. ncbi Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function
    Michael R Lucey
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53792 5124, USA
    Am J Gastroenterol 103:1698-706. 2008
    ....
  54. doi Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: the value of artificial ascites
    Hyunchul Rhim
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam Gu, Seoul, Korea
    Abdom Imaging 34:371-80. 2009
    ..RF ablation with assistance of the use of artificial ascites is a simple and safe technique for treating a hepatic dome tumor abutting the diaphragm...
  55. ncbi Malignant ascites: past, present, and future
    Rony A Adam
    Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA 30303, USA
    J Am Coll Surg 198:999-1011. 2004
  56. doi Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites
    Jasmohan S Bajaj
    Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, McGuire VA Medical Center, Virginia Commonwealth University, Richmond, Virginia 23221, USA
    Am J Gastroenterol 104:1130-4. 2009
    Spontaneous bacterial peritonitis (SBP) is a frequent complication of cirrhosis. Bacterial contamination of ascites fluid leading to SBP is caused by bacterial translocation with subsequent bacteremia...
  57. doi Differential gene expression of proinflammatory chemokines and cytokines in lungs of ascites-resistant and -susceptible broiler chickens following intravenous cellulose microparticle injection
    Krishna R Hamal
    Department of Poultry Science, University of Arkansas, Fayetteville, AR 72701, USA
    Vet Immunol Immunopathol 133:250-5. 2010
    ..of microparticles (MPs) is a tool to reveal susceptibility to pulmonary hypertension (PH) syndrome (PHS, ascites) in broilers. After injection MPs get lodged in pulmonary arterioles and cause localized inflammation...
  58. ncbi Development of an experimental model of induced bacterial peritonitis in cirrhotic rats with or without ascites
    Elisabet Sánchez
    Liver Unit, Hospital de la Santa Creu i Sant Pau, Autonomous University, Barcelona, Spain
    Am J Gastroenterol 102:1230-6. 2007
    ..Spontaneous bacterial peritonitis (SBP) is a severe complication of cirrhotic patients associated with a high mortality...
  59. ncbi Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer
    Frank Chih Kang Chen
    Department of Gynecology and Obstetrics Charité University Medicine Berlin Campus Virchow Klinikum Augustenburger Platz 1, 13353 Berlin, Germany
    Anticancer Res 29:1575-8. 2009
    ..The aim of this study was to investigate the influence of sex hormone levels on tumor biology and patients' outcome in ovarian cancer...
  60. ncbi Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1
    Takayuki Yamada
    Laboratory of Signal Transduction, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi 371 8512, Japan
    J Biol Chem 279:6595-605. 2004
    Cytokines and growth factors in malignant ascites are thought to modulate a variety of cellular activities of cancer cells and normal host cells...
  61. ncbi Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS
    P T Masiakos
    Pediatric Surgical Research Laboratories, Department of Surgery, The Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    Clin Cancer Res 5:3488-99. 1999
    Six human ovarian cancer cell lines and samples of ascites cells isolated from 27 patients with stage III or IV ovarian papillary serous cystadenocarcinoma were studied individually to test whether recombinant human Mullerian inhibiting ..
  62. ncbi Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients
    Trevor G Shepherd
    Department of Pharmacology, Dalhousie University, 5850 College Street, Halifax, Nova Scotia, Canada B3H 1X5
    Nat Protoc 1:2643-9. 2006
    ..A simple protocol of obtaining primary epithelial ovarian cancer (EOC) cells from the ascites fluid removed from patients with high-grade ovarian cancer is also described...
  63. pmc Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation
    Daniel Gotthardt
    Department of Internal Medicine IV, University Hospital of Heidelberg, Heidelberg, Germany
    BMC Gastroenterol 9:72. 2009
    ..The relative shortage of organ donors renders the allocation algorithms of organs essential. The optimal strategy based on scoring systems and/or waiting time is still under debate...
  64. doi Ascites syndrome in broilers: physiological and nutritional perspectives
    A Baghbanzadeh
    Section of Physiology, Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
    Avian Pathol 37:117-26. 2008
    ..If this is not done, inefficient production and several metabolic diseases such as ascites become apparent...
  65. ncbi Evaluation of minimally invasive indices for predicting ascites susceptibility in three successive hatches of broilers exposed to cool temperatures
    R F Wideman
    Department of Poultry Science, University of Arkansas, Fayetteville 72701, USA
    Poult Sci 77:1565-73. 1998
    ..hatches were exposed to cool temperatures to amplify the incidence of pulmonary hypertension syndrome (PHS, ascites)...
  66. ncbi Natural history of patients hospitalized for management of cirrhotic ascites
    Ramon Planas
    Liver Section, Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    Clin Gastroenterol Hepatol 4:1385-94. 2006
    Since the International Ascites Club published the diagnostic criteria of refractory ascites (RA) and hepatorenal syndrome (HRS), there have been few studies assessing the natural history of ascites...
  67. doi In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry
    Sarah Elschenbroich
    Ontario Cancer Institute, University Health Network, Toronto, Canada
    J Proteome Res 10:2286-99. 2011
    ..We built on our experience in analyzing ovarian cancer ascites and present an analysis pipeline that combines discovery-based proteomics, bioinformatics prioritization and ..
  68. doi Coexistence of struma ovarii with marked ascites and elevated CA-125 levels: case report and literature review
    Mabel Po Mui
    Department of Obstetrics and Gynaecology, Centro Hospitalar Conde de S Januario, Macao, People s Republic of China
    Arch Gynecol Obstet 279:753-7. 2009
    Struma ovarii is a rare form of ovarian neoplasm and consists mainly of thyroid tissue. Ascites has been reported in approximately one-third of all the cases...
  69. ncbi Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation
    Gianni Testino
    Unit of Hepato Gastroenterology Monoblocco 12, S Martino Hospital, Piazzale R Benzi 16132, Genova, Italy
    Hepatogastroenterology 50:1753-5. 2003
    ..Its role in the management of refractory ascites and hepatorenal syndrome still awaits further prospective studies...
  70. ncbi [Eosinophilic enteritis as a rare cause of ascites]
    A Bouhmidi
    Hospital Clínico Universitario San Cecilio Granada España
    Gastroenterol Hepatol 26:480-1. 2003
    ..depend on the affected layers and range from barely perceptible symptoms to intestinal obstruction or ascites. We present the case of an 18-year-old woman who showed abdominal ascites as a rare form of presentation with ..
  71. ncbi Rapid growth problems: ascites and skeletal deformities in broilers
    R J Julian
    Department of Pathology, Ontario Veterinary College, University of Guelph, Canada
    Poult Sci 77:1773-80. 1998
    ..In the chicken, sudden death syndrome (flip-over) and pulmonary hypertension syndrome resulting in ascites are the most important...
  72. doi Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation
    Kiyomi Takaishi
    Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
    Cancer Sci 101:2128-36. 2010
    b>Ascites macrophages in advanced epithelial ovarian cancer (AdEOC) are involved in cancer metastasis and progression by modifying the tumor microenvironment...
  73. ncbi A prospective evaluation of catheter probe EUS for the detection of ascites in patients with gastric carcinoma
    Kent Man Chu
    Current affiliations Division of Upper Gastrointestinal Surgery, Department of Surgery, University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong, China
    Gastrointest Endosc 59:471-4. 2004
    Gastric carcinoma is known for its propensity to spread to the peritoneum. This study assessed the value of EUS in the detection of ascites not visible on CT in patients with gastric carcinoma.
  74. ncbi Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer
    Raquel De Souza
    Department of Pharmaceutical Sciences, University of Toronto, Ontario, Canada
    Mol Cancer Ther 9:1820-30. 2010
    ..is considerably more efficacious than intermittent therapy, resulting in a greater decrease in tumor burden and ascites fluid accumulation...
  75. ncbi Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity
    Robert L Giuntoli
    The Kelly Gynecologic Oncology Service, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Phipps 281, Baltimore, Maryland 21287, USA
    Anticancer Res 29:2875-84. 2009
    To identify immunosuppressive elements present in ovarian cancer associated ascites.
  76. ncbi Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial
    H Navabi
    Cancer Services, Velindre NHS Trust, Cardiff, UK
    Blood Cells Mol Dis 35:149-52. 2005
    ..undergoing chemotherapy using a combination of a Toll-like receptor 3 (TLR3) agonist and tumour-associated ascites-derived exosomes...
  77. ncbi HLA-G is a potential tumor marker in malignant ascites
    Gad Singer
    Department of Pathology, Johns Hopkins University Medical Institutions, Baltimore Maryland 21231, USA
    Clin Cancer Res 9:4460-4. 2003
    Molecular approaches as supplements to cytological examination of malignant ascites may play an important role in the clinical management of cancer patients...
  78. doi Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center
    Xiao jun Yang
    Department of Oncology, Zhongnan Hospital Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors and Hubei Cancer Clinical Study Center, Wuchang District, Wuhan, Hubei Province, China
    J Surg Oncol 101:457-64. 2010
    ..This work was to evaluate cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer (GC)...
  79. ncbi VEGF expression and the effect of NSAIDs on ascites cell proliferation in the hen model of ovarian cancer
    M E Urick
    Department of Animal Science, Cornell University, Ithaca, NY 14853, USA
    Gynecol Oncol 110:418-24. 2008
    We aimed to determine the expression of vascular endothelial growth factor (VEGF) and the effect of nonsteroidal anti-inflammatory drugs (NSAIDs) on the proliferation of cells isolated from ascites in the hen model of ovarian cancer.
  80. ncbi Ascites as a predictor of ovarian malignancy
    Jane Shen-Gunther
    Gynecologic Surgery and Oncology, 2911 N Tenaya Way, Suite 105, Las Vegas, NV 89128, USA
    Gynecol Oncol 87:77-83. 2002
    To determine the utility of ascites as a predictor of ovarian malignancy and define its relationship with the histologic type of ovarian tumor (benign, borderline, or malignant) and stage of disease.
  81. ncbi A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites
    M Rossle
    Medizinische Klinik II, Albrecht Ludwigs Universität, Department of Gastroenterology, Freiburg, Germany
    N Engl J Med 342:1701-7. 2000
    In patients with cirrhosis and ascites, creation of a transjugular intrahepatic portosystemic shunt may reduce the ascites and improve renal function...
  82. ncbi Malignant ascites: systematic review and guideline for treatment
    Gerhild Becker
    Department of Internal Medicine II, University Hospital of Freiburg, Hugstetter Str 55, D 79106 Freiburg, Germany
    Eur J Cancer 42:589-97. 2006
    A guideline on the management of symptomatic malignant ascites by abdominal paracentesis, diuretics and peritoneovenous shunting, based on a systematic review of the literature is presented. Thirty-two relevant studies were identified...
  83. ncbi Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice
    Mohammad Hossein Pourgholami
    Cancer Research Laboratories, Department of Surgery, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia
    Clin Cancer Res 12:1928-35. 2006
    Angiogenesis and vessel hyperpermeability are the two factors leading to the formation of ascites. Vascular endothelial growth factor (VEGF) plays a pivotal role in malignant ascites formation...
  84. doi Ascites and spontaneous bacterial peritonitis: an Asian perspective
    Jung Min Lee
    Department of Internal Medicine, Brain Korea 21 Project for Medical Science, Seoul, South Korea
    J Gastroenterol Hepatol 24:1494-503. 2009
    b>Ascites is the most common complication of liver cirrhosis, and it develops as a consequence of portal hypertension and splanchnic vasodilatation...
  85. ncbi Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema
    H Farkas
    Kutvolgyi Clinical Centre, Allergology and Angio oedema Outpatient Clinic, Semmelweis University, Budapest, Hungary
    Eur J Gastroenterol Hepatol 13:1225-30. 2001
    Hereditary angioneurotic oedema (HAE) is a rare cause of ascites. As acute abdominal attacks of the disease can mimic surgical emergencies, prompt and accurate diagnosis is essential...
  86. ncbi A sequential study of serum bacterial DNA in patients with advanced cirrhosis and ascites
    Rubén Francés
    Unidad Hepática Sección de Inmunología, Alicante, Spain
    Hepatology 39:484-91. 2004
    ..main pathogenic mechanism leading to spontaneous bacterial peritonitis in patients with advanced cirrhosis and ascites. However, to the authors' knowledge there is no information regarding the characteristics of this process in ..
  87. pmc Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130)
    S Dessi
    Istituto di Patologia Sperimentale, Universita degli Studi di Cagliari, Italy
    Br J Cancer 66:787-93. 1992
    ..of cholesterol has been investigated in tumour cells, ascitic fluid and blood serum during the growth of an ascites hepatoma (Yoshida AH-130) in the rat...
  88. ncbi Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study
    Andrea De Gottardi
    Division of Gastroenterology and Hepatology, University Hospital of Geneva, Geneva, Switzerland
    Clin Gastroenterol Hepatol 7:906-9. 2009
    ..Complications and technical problems of paracentesis in cirrhotic patients are infrequent. However, the severity and the incidence of these events and their risk factors have not been assessed prospectively...
  89. ncbi Patients with ovarian cancer have elevated (51)Cr-EDTA plasma clearance early post-operatively
    S S Nielsen
    Department of Clinical Physiology and Nuclear Medicine, Skejby Sygehus, Aarhus University Hospital, Brendstrupgaardsvej, DK 8200 Aarhus N, Denmark
    Nucl Med Commun 23:917-20. 2002
    ..Additionally, age, height, weight, cancer stage, ascites and tumour histology were noted...
  90. ncbi Spontaneous ovarian hyperstimulation syndrome in a normal singleton pregnancy
    Ozer Oztekin
    Department of Obstetrics and Gynecology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
    Taiwan J Obstet Gynecol 45:272-5. 2006
    ..However, OHSS may rarely be associated with a spontaneous ovulatory cycle, usually in the case of multiple gestations, hypothyroidism or polycystic ovary syndrome...
  91. doi Interferon-gamma release assay in the ascites: Early hint for diagnosis of abdominal tuberculosis
    R Lorenz
    Dept of Internal Medicine, University Hospital Ulm, Germany
    Infection 38:69-72. 2010
    We report on a 20-year-old woman with abdominal tuberculosis.Standard microbiological examination of ascites showed no acid-fast bacilli (AFB), and analysis for the Mycobacterium tuberculosis (MTB)-complex DNA by PCR was negative...
  92. ncbi Determination of the necessary total protein substitution requirements in patients with advanced stage ovarian cancer and ascites, undergoing debulking surgery. Correlation with plasma proteins
    George Vorgias
    Department of Gynecology, Metaxa Memorial Cancer Hospital, Piraeus, Greece
    Ann Surg Oncol 14:1919-23. 2007
    b>Ascites is common in patients with advanced ovarian carcinoma (AOC). Its drainage during surgery affects plasma proteins...
  93. ncbi Torsion of a giant omental cyst mimicking ascites
    Suat Fitoz
    Department of Radiology, Ankara University School of Medicine, Dikimevi, Ankara 06100, Turkey
    J Clin Ultrasound 35:85-7. 2007
    ..The cyst occupied nearly the whole abdomen and mimicked massive ascites on sonography...
  94. pmc Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites
    Ming Chen Ba
    Department of Abdominal Surgery Section 2, Cancer Hospital of Guangzhou Medical College, Guangzhou 510095, Guangdong Province, China
    World J Gastroenterol 16:1901-7. 2010
    ..procedure, feasibility and effects of laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy (CHIPC) in treatment of malignant ascites induced by peritoneal carcinomatosis from gastric cancers.
  95. ncbi Effect of cold stress on broilers selected for resistance or susceptibility to ascites syndrome
    J M Balog
    USDA ARS PP and PSR, Fayetteville, Arkansas 72701, USA
    Poult Sci 82:1383-7. 2003
    Genetic selection for an ascites-resistant line of broilers is seen as a permanent solution to the ascites problem...
  96. ncbi Effect of ascites on bone density measurement in cirrhosis
    Eternity D Labio
    NHMRC Center of Clinical Research Excellence to Improve Outcome in Chronic Liver Disease, AW Morrow Gastroenterology and Liver Center, University of Sydney, Camperdown, New South Wales, Australia
    J Clin Densitom 10:391-4. 2007
    Cirrhosis is an independent risk factor for the development of osteoporosis. The presence of ascites in patients with cirrhosis may affect the accuracy of bone density measurement in the spine...
  97. ncbi Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients
    M Valle
    Department of Surgical Oncology, Digestive Branch, Regina Elena National Cancer Institute, Rome, Italy
    J Surg Oncol 100:331-4. 2009
    Malignant ascites is a debilitating condition affecting cancer patients in their terminal stage of disease. Recently, laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) was introduced as a new approach...
  98. doi Paracrine action of sFLT-1 secreted by stably-transfected Ehrlich ascites tumor cells and therapy using sFLT-1 inhibits ascites tumor growth in vivo
    Sunitha Ramachandra
    Department of Studies in Biotechnology, University of Mysore, Mysore, 570006 Karanataka, India
    J Gene Med 11:422-34. 2009
    ..In the present study, we have developed and tested strategies targeted specifically to VEGF for the treatment of ascites formation.
  99. pmc Ascites due to right atrial myxoma in a haemodialysis patient
    Anindya Banerjee
    University College London, Centre for Nephrology, Royal Free Hospital, London, UK
    BMC Nephrol 7:4. 2006
    ..Persistent fluid overload in patients on renal replacement therapy despite good dialysis adequacy or obvious cardiac dysfunction should prompt a search for rarer causes...
  100. ncbi Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients
    Inyoung Song
    Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50, IlWon Dong, Kangnam Ku, Seoul 135 710, Korea
    Eur Radiol 19:2630-40. 2009
    ..was to assess the feasibility, safety and efficacy of radiofrequency ablation (RFA) with the use of artificial ascites for hepatocellular carcinoma (HCC) adjacent to the diaphragm and gastrointestinal tract...
  101. ncbi Eosinophilic ascites in a patient with toxocara canis infection. A case report
    Olimpia Chira
    3rd Medical Clinic, and University of Medicine and Pharmacy, Cluj Napoca, Romania
    Rom J Gastroenterol 14:397-400. 2005
    We report the case of a young female patient, admitted for a recent ascites of unknown origin. The acute onset was with colicky abdominal pain and peritoneal effusion, which led to the suspicion of perforated ulcer...

Research Grants77

  1. Molecular mechanism of antiangiogenic properties of gold nanoparticle
    Priyabrata Mukherjee; Fiscal Year: 2010
    ..It is likely that it will bind to all the pro-angiogenic heparin-binding growth factors present in the ascites and inhibit their function...
  2. Molecular mechanism of antiangiogenic properties of gold nanoparticle
    Priyabrata Mukherjee; Fiscal Year: 2009
    ..It is likely that it will bind to all the pro-angiogenic heparin-binding growth factors present in the ascites and inhibit their function...
  3. RISK FACTORS OF INTESTINAL MICROSPORIDIOSIS IN PERSONS INFECTED W/ HIV
    ELIZABETH DIDIER; Fiscal Year: 2000
    ..Athymic mice developed wasting (cachexia) and ascites and died 15 - 60 days after intraperitoneal inoculation with 5 x 107 - 1 x 104 V. corneae organisms...
  4. EFFECT OF NALOXONE ON RENAL FUNCTIONS IN LIVER CIRRHOSIS
    David Leehey; Fiscal Year: 1992
    ..increases creatinine clearance and water and electrolyte excretion in water-loaded patients with cirrhosis and ascites. Question 1: Are the diuretic effects of the opioid antagonist naloxone in patients with cirrhosis and ascites ..
  5. EFFECT OF NALOXONE ON RENAL FUNCTIONS IN LIVER CIRRHOSIS
    David Leehey; Fiscal Year: 1993
    ..increases creatinine clearance and water and electrolyte excretion in water-loaded patients with cirrhosis and ascites. Question 1: Are the diuretic effects of the opioid antagonist naloxone in patients with cirrhosis and ascites ..
  6. ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
    Roberto Groszmann; Fiscal Year: 2000
    ..but because it may prevent or delay the development of other complications of portal hypertension, such a ascites. This ongoing multi-center, prospective, randomized, placebo-controlled, double-blind trial was designed with the ..
  7. ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
    Roberto Groszmann; Fiscal Year: 2001
    ..but because it may prevent or delay the development of other complications of portal hypertension, such a ascites. This ongoing multi-center, prospective, randomized, placebo-controlled, double-blind trial was designed with the ..
  8. ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
    Roberto Groszmann; Fiscal Year: 2002
    ..but because it may prevent or delay the development of other complications of portal hypertension, such a ascites. This ongoing multi-center, prospective, randomized, placebo-controlled, double-blind trial was designed with the ..
  9. ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
    Roberto Groszmann; Fiscal Year: 2003
    ..but because it may prevent or delay the development of other complications of portal hypertension, such a ascites. This ongoing multi-center, prospective, randomized, placebo-controlled, double-blind trial was designed with the ..
  10. Development of therapeutic monoclonal antibody to the bioactive lipid lysophospha
    Rosalia Matteo; Fiscal Year: 2009
    ..LPA is elevated in sera and ascites fluid of patients with early and late stage disease...
  11. Identification of pancreatic cancer specific high affinity targeting ligands
    PAPPANAICKEN KUMARESAN; Fiscal Year: 2007
    ..can be used for imaging and to trap circulating cancer cells in the biological fluids such as blood, pancreatic ascites and stool...
  12. ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
    Roberto Groszmann; Fiscal Year: 1999
    ..but because it may prevent or delay the development of other complications of portal hypertension, such a ascites. This ongoing multi-center, prospective, randomized, placebo-controlled, double-blind trial was designed with the ..
  13. STRUCTURE/BIOSYNTHESIS OF TUMOR SIALOMUCIN COMPLEX
    KERMIT CARRAWAY; Fiscal Year: 1999
    ..is focused on a novel cell surface glycoprotein complex (sialomucin complex, SMC), originally isolated from ascites sublines of the highly metastatic 13762 rat mammary adenocarcinoma...
  14. STRUCTURE/BIOSYNTHESIS OF TUMOR SIALOMUCIN COMPLEX
    KERMIT CARRAWAY; Fiscal Year: 1999
    ..is focused on a novel cell surface glycoprotein complex (sialomucin complex, SMC), originally isolated from ascites sublines of the highly metastatic 13762 rat mammary adenocarcinoma...
  15. Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases
    SCOTT EBLEN; Fiscal Year: 2009
    ..We generated phospho-specific antibodies and have shown SPF45 phosphorylation in human ascites and in cell lines in response to chemotherapeutic drugs, oxidative stress, phorbol esters and UV irradiation...
  16. Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases
    Scott T Eblen; Fiscal Year: 2010
    ..We generated phospho-specific antibodies and have shown SPF45 phosphorylation in human ascites and in cell lines in response to chemotherapeutic drugs, oxidative stress, phorbol esters and UV irradiation...
  17. TRANSJUGULAR PORTASYSTEMIC SHUNTS/PARACENTESIS FOR TREATMENT OF ASCITES
    Arun Sanyal; Fiscal Year: 2000
    ..The patients will be seen 1,2,and 4 weeks after insertion of the shunt, and monthly for 12 months. Then they'll be seen every three months. Special diets will be assigned and lab tests will be done at every visit. ..
  18. DETERMINANTS OF SODIUM RETENTION IN CIRRHOSIS
    WILLIAM RECTOR; Fiscal Year: 1992
    The cause of ascites in patients with cirrhosis is not established...
  19. DETERMINANTS OF RENAL SODIUM RETENTION IN CIRRHOSIS
    WILLIAM RECTOR; Fiscal Year: 1990
    The cause of ascites in patients with cirrhosis is not established...
  20. PREVENTION OF ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKER
    Roberto Groszmann; Fiscal Year: 1993
    ..time beta- blocker therapy is initiated, since in these studies patients already have varices and frequently have ascites. Experimental studies have shown that propranolol therapy, administered in the early stages of portal ..
  21. OVARIAN CARCINOMA--ROLE OF LAMININ AND ITS RECEPTORS
    Amy Skubitz; Fiscal Year: 1993
    ..longer adhere in a normal fashion to the BM; rather, they release from the BM, seed other sites, develop into an ascites form, or invade into the stroma of the ovary...
  22. HER2 LIGAND IN HUMAN BREAST TUMORS
    KERMIT CARRAWAY; Fiscal Year: 2001
    ..is focused on a novel cell surface glycoprotein complex (sialomucin complex, SMC), originally isolated from ascites sublines of the highly metastatic 13762 rat mammary adenocarcinoma...
  23. HER2 LIGAND IN HUMAN BREAST TUMORS
    KERMIT CARRAWAY; Fiscal Year: 2001
    ..is focused on a novel cell surface glycoprotein complex (sialomucin complex, SMC), originally isolated from ascites sublines of the highly metastatic 13762 rat mammary adenocarcinoma...
  24. HER2 LIGAND IN HUMAN BREAST TUMORS
    KERMIT CARRAWAY; Fiscal Year: 2000
    ..is focused on a novel cell surface glycoprotein complex (sialomucin complex, SMC), originally isolated from ascites sublines of the highly metastatic 13762 rat mammary adenocarcinoma...
  25. HER2 LIGAND IN HUMAN BREAST TUMORS
    KERMIT CARRAWAY; Fiscal Year: 1999
    ..is focused on a novel cell surface glycoprotein complex (sialomucin complex, SMC), originally isolated from ascites sublines of the highly metastatic 13762 rat mammary adenocarcinoma...
  26. Noninvasive and Accurate Measurement of Portal Hypertension
    Flemming Forsberg; Fiscal Year: 2009
    ..Common complications of portal hypertension include gastroesophageal varices, ascites, and portasystemic encephalopathy...
  27. ALDOSTERONE, RENIN AND PROSTAGLANDINS IN MAN
    Richard Horton; Fiscal Year: 1980
    ..In preliminary studies we find that ascites patients have 10-fold increase in PGE, that prostaglandin inhibitors reduce renin (PRA) and aldosterone, reverse ..
  28. Noninvasive and Accurate Measurement of Portal Hypertension
    Flemming Forsberg; Fiscal Year: 2010
    ..Common complications of portal hypertension include gastroesophageal varices, ascites, and portasystemic encephalopathy...
  29. METHODOLOGIC RESEARCH IN SIMULATING COMPLEX DISEASE
    Mark Roberts; Fiscal Year: 1991
    ..of disease-related death, and produces substantial morbidity and decreases quality of life when patients develop ascites, encephalopathy or bleeding varices...
  30. TUMOR ANTIGENS IN PANCREATIC CANCER
    TSANN CHU; Fiscal Year: 1980
    ..antigens are to be isolated from plasma membrane fraction of the pancreatic tumors, from the extracellular fluid (ascites fluid) and tumor tissues of pancreatic cancer patients...
  31. Effect of Cirrhosis and Shunts on Drug Disposition
    J Gorski; Fiscal Year: 2002
    ..major complications of cirrhosis such as bleeding from gastroesophageal varices, hepatic encephalopathy, and ascites. Transjugular intrahepatic portosystemic shunts (TIPS) and other surgical shunts are performed to manage these ..
  32. Effect of Cirrhosis and Shunts on Drug Disposition
    J Gorski; Fiscal Year: 2004
    ..major complications of cirrhosis such as bleeding from gastroesophageal varices, hepatic encephalopathy, and ascites. Transjugular intrahepatic portosystemic shunts (TIPS) and other surgical shunts are performed to manage these ..
  33. Effect of Cirrhosis and Shunts on Drug Disposition
    Stephen Hall; Fiscal Year: 2006
    ..major complications of cirrhosis such as bleeding from gastroesophageal varices, hepatic encephalopathy, and ascites. Transjugular intrahepatic portosystemic shunts (TIPS) and other surgical shunts are performed to manage these ..
  34. Effect of Cirrhosis and Shunts on Drug Disposition
    J Gorski; Fiscal Year: 2005
    ..major complications of cirrhosis such as bleeding from gastroesophageal varices, hepatic encephalopathy, and ascites. Transjugular intrahepatic portosystemic shunts (TIPS) and other surgical shunts are performed to manage these ..
  35. Effect of Cirrhosis and Shunts on Drug Disposition
    J Gorski; Fiscal Year: 2003
    ..major complications of cirrhosis such as bleeding from gastroesophageal varices, hepatic encephalopathy, and ascites. Transjugular intrahepatic portosystemic shunts (TIPS) and other surgical shunts are performed to manage these ..
  36. CYTOTOXIC FACTOR(S) FROM HUMAN OVARIAN ADENOCARCINOMA
    BERTRUM SHEID; Fiscal Year: 1980
    ..of inhibitor(s) of cellular proliferation in the cytosol of human ovarian adenocarcinoma cells, and in the ascites fluid of women with disseminated ovarian cancer...
  37. Synergistic actions by multiple Toll-like receptors in alcoholic liver disease
    Ekihiro Seki; Fiscal Year: 2010
    ..Not only LPS, but also bacterial DNA levels in blood and ascites are elevated in patients with alcoholic-induced liver cirrhosis...
  38. OCULAR SURFACE PROTECTION BY SIALOMUCIN COMPLEX
    KERMIT CARRAWAY; Fiscal Year: 2001
    ..SMC was originally identified and isolated from membranes of ascites sublines of the highly metastatic 13762 rat mammary adenocarcinoma and is composed of a mucin subunit ASGP-1 (..
  39. OCULAR SURFACE PROTECTION BY SIALOMUCIN COMPLEX
    KERMIT CARRAWAY; Fiscal Year: 2002
    ..SMC was originally identified and isolated from membranes of ascites sublines of the highly metastatic 13762 rat mammary adenocarcinoma and is composed of a mucin subunit ASGP-1 (..
  40. OCULAR SURFACE PROTECTION BY SIALOMUCIN COMPLEX
    KERMIT CARRAWAY; Fiscal Year: 1999
    ..SMC was originally identified and isolated from membranes of ascites sublines of the highly metastatic 13762 rat mammary adenocarcinoma and is composed of a mucin subunit ASGP-1 (..
  41. Novel, cost-effective production of immunoaffinity Abs
    Scott Franklin; Fiscal Year: 2006
    ..including culture of hybridomas, re-introduction of hybridomas into mice and subsequent generation of ascites and transfection of mammalian cell lines with specific heavy and light chain antibody genes...
  42. Peritumorally transformable nanoparticles for intraperitoneal chemotherapy of ova
    Yoon Yeo; Fiscal Year: 2010
    ..Simultaneously, in Aim 2, we will determine in-vivo MMP levels in normal tissues, ascites, and tumor tissues in an orthotopic xenograft model of human ovarian cancer...
  43. Peritumorally transformable nanoparticles for intraperitoneal chemotherapy of ova
    Yoon Yeo; Fiscal Year: 2009
    ..Simultaneously, in Aim 2, we will determine in-vivo MMP levels in normal tissues, ascites, and tumor tissues in an orthotopic xenograft model of human ovarian cancer...
  44. CANCER, LIPID, STRESS AND THYROID RESEARCH
    MILDRED OFOSU; Fiscal Year: 1991
    ..and histochemical studies of the combined application of iproplatin, carboplatin and platinum-thymine on ascites sarcoma. Dose-limiting side effects in combination therapy will be monitored...
  45. ECTO 5'-NUCLEOTIDASE AS A CELL SURFACE REPORTER
    KERMIT CARRAWAY; Fiscal Year: 1980
    ..Recent studies from our laboratory have shown that the coperativity in mammary ascites tumor cells is sensitive to drugs which perturb the cellular cytoskeleton and to intracellular Ca ions...
  46. MECHANISM OF NANAASE-ENHANCED TUMOR IMMUNOGENICITY
    JACK PINCUS; Fiscal Year: 1980
    ..We have developed a chemoimmunotherapy model for treating L1210 ascites tumors in DBA/2J mice by combining 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosurea (MeCCNU) with NANAase-..
  47. CORE--PATHOLOGY
    Russell Broaddus; Fiscal Year: 2003
    ..Aim 3 is to establish a blood/urine/ascites fluid repository from patients undergoing hysterectomy for endometrial cancer and endometrial hyperplasia...
  48. TRIPTYCENE ANALOGS--NOVEL BIFUNCTIONAL ANTICANCER DRUGS
    Jean Pierre Perchellet; Fiscal Year: 2004
    ..TT2 derivatives can inhibit tumor development in vivo and prolong the survival of mice challenged with ascites (L1210) or solid tumors with metastatic potential (Lewis lung carcinoma and B16F10 melanoma)...
  49. TRIPTYCENE ANALOGS--NOVEL BIFUNCTIONAL ANTICANCER DRUGS
    Jean Pierre Perchellet; Fiscal Year: 2002
    ..TT2 derivatives can inhibit tumor development in vivo and prolong the survival of mice challenged with ascites (L1210) or solid tumors with metastatic potential (Lewis lung carcinoma and B16F10 melanoma)...
  50. TRIPTYCENE ANALOGS--NOVEL BIFUNCTIONAL ANTICANCER DRUGS
    Jean Pierre Perchellet; Fiscal Year: 2001
    ..TT2 derivatives can inhibit tumor development in vivo and prolong the survival of mice challenged with ascites (L1210) or solid tumors with metastatic potential (Lewis lung carcinoma and B16F10 melanoma)...
  51. Liver Derived Microparticles In Cirhossis Pathogenesis
    RAFAL WITEK; Fiscal Year: 2009
    ..of cirrhosis, including cutaneous spider telangectases, cachexia, increased intestinal permeability, ascites and the hepatorenal syndrome, the portopulmonary syndrome, and hepatic encephalopathy...
  52. INTERFERON-INDUCED PROTEINS IN MOUSE AND HUMAN CELLS
    SOHAN GUPTA; Fiscal Year: 1980
    ..In such studies, we have already detected certain proteins that are induced in mouse cells (Ehrlich ascites, L929) and in human cells (FS4, GM258) upon treatment with homologous interferon...
  53. OCULAR SURFACE PROTECTION BY SIALOMUCIN COMPLEX
    KERMIT CARRAWAY; Fiscal Year: 2000
    ..SMC was originally identified and isolated from membranes of ascites sublines of the highly metastatic 13762 rat mammary adenocarcinoma and is composed of a mucin subunit ASGP-1 (..
  54. PATHOGENESIS AND THERAPY OF B19-INDUCED HYDROPS FETALIS
    Cathy Carlson; Fiscal Year: 2000
    ..e., presence of ascites, pleural or pericardial effusions) if present...
  55. Central Kappa Opioid Neural Regulation of Cardiovascular and Renal Function
    Helmut B Gottlieb; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): In certain pathophysiological states (e.g., cirrhoses with ascites), changes in the integrity of arterial circulation can lead to profound changes in renal excretion of fluid and electrolytes via the ..
  56. PATHOGENESIS AND THERAPY OF B19-INDUCED HYDROPS FETALIS
    M O SULLIVAN; Fiscal Year: 1999
    ..e., presence of ascites, pleural or pericardial effusions) if present...
  57. MODEL TO TEST THE THERAPEUTIC VALUE OF TOXIN CONJUGATES
    VICTOR RASO; Fiscal Year: 1990
    ..A single low dose of this toxin rapidly eliminates both the ascites plus solid tumors and consistently cures these mice...
  58. FUNCTION OF MITOCHONDRIAL OUTER MEMBRANE
    Dipak Haldar; Fiscal Year: 1992
    ..We will examine if Ehrlich ascites tumor cells, which show a random distribution of fatty acids in the sn-1 and sn-2 positions of some of their ..
  59. ELIMINATION OF EXTRACHROMOSOMAL DNA FROM OVARIAN CANCER
    Daniel Von Hoff; Fiscal Year: 1992
    ..To accomplish this specific aim, women with advanced refractory ovarian cancer with refractory malignant ascites requiring frequent paracentesis for comfort, will be treated with hydroxyurea...
  60. Gene Regulation for Drug Targeting in AML
    Manohar Ratnam; Fiscal Year: 2009
    ..The ATRA effect conferred a substantial therapeutic benefit, on FR-targeted liposomal doxorubicin, in a mouse ascites tumor model of AML...
  61. Gene Regulation for Drug Targeting in AML
    Manohar Ratnam; Fiscal Year: 2006
    ..The ATRA effect conferred a substantial therapeutic benefit, on FR-targeted liposomal doxorubicin, in a mouse ascites tumor model of AML...
  62. LYMPHOCYTE/TUMOR INTERACTIONS IN SCID/HU CHIMERIC MICE
    Albert Donnenberg; Fiscal Year: 1993
    ..The development of this model depends upon three elements: 1) our ability to separate human malignant ovarian ascites into highly enriched populations of tumor cells, lymphocytes, and monocytes by counterflow centrifugal ..
  63. Gene Regulation for Drug Targeting in AML
    Manohar Ratnam; Fiscal Year: 2005
    ..The ATRA effect conferred a substantial therapeutic benefit, on FR-targeted liposomal doxorubicin, in a mouse ascites tumor model of AML...
  64. Gene Regulation for Drug Targeting in AML
    Manohar Ratnam; Fiscal Year: 2007
    ..The ATRA effect conferred a substantial therapeutic benefit, on FR-targeted liposomal doxorubicin, in a mouse ascites tumor model of AML...
  65. MEDULLARY HEMODYNAMICS AND RENAL SODIUM EXCRETION
    Shyan Yih Chou; Fiscal Year: 1980
    ..retention of a salt-retaining model, the dog with chronic constriction of the thoracic inferior vena cava with ascites (caval dog), and is associated with no change in the cortical blood flow distribution...
  66. REGULATION OF CSF 1 AND UROKINASE IN OVARIAN CANCER
    SETSUKO CHAMBERS; Fiscal Year: 1999
    ..Moreover studies of the role of uPA, its receptor, and its inhibitors in ascites of ovarian cancer patients suggests that uPA is an important protease in the biology of ovarian cancer...
  67. MECHANISM OF IMMUNOSUPPRESSION BY PLASMACYTOMAS
    HELGA HAVAS; Fiscal Year: 1980
    ..In order to achieve these goals, we have studied the suppressive activity of serum and ascites from tumor-bearing mice and of cell extracts of lymphoid tissue...
  68. STUDIES OF MECHANISMS AND TREATMENT OF LIVER DISEASE
    Arun Sanyal; Fiscal Year: 2000
    ..performed: (1) a randomized prospective multi-center trial of total paracenteses (TP) vs TP + TIPS for refractory ascites of which he is the principal investigator...
  69. THROMBOEMBOLISM: NON-INVASIVE DIAGNOSIS
    SCOTT ROSEBROUGH; Fiscal Year: 1990
    ..We have obtained hybridoma clone culture medium and ascites fluid containing this Mab, purified it by immunoaffinity chromatography (IAFC), determined its avidity for dog ..
  70. TRIPTYCENE ANALOGS--NOVEL BIFUNCTIONAL ANTICANCER DRUGS
    Jean Pierre Perchellet; Fiscal Year: 2000
    ..TT2 derivatives can inhibit tumor development in vivo and prolong the survival of mice challenged with ascites (L1210) or solid tumors with metastatic potential (Lewis lung carcinoma and B16F10 melanoma)...
  71. CELL DEATH, CHALONES, AND CYTOTOXIC METABOLITES
    Ralph Parchment; Fiscal Year: 1991
    ..Preliminary data obtained with the cyst fluid from blastocyst-like embryoid bodies of the ascites form of a teratocarcinoma suggest that cytotoxic polyamine metabolites, generated by the activities of amine ..
  72. TRIPTYCENE ANALOGS--NOVEL BIFUNCTIONAL ANTICANCER DRUGS
    Jean Pierre Perchellet; Fiscal Year: 2003
    ..TT2 derivatives can inhibit tumor development in vivo and prolong the survival of mice challenged with ascites (L1210) or solid tumors with metastatic potential (Lewis lung carcinoma and B16F10 melanoma)...